胃癌D2根治术后SOX与XELOX辅助化疗有效性和安全性比较的回顾性队列研究  

A Retrospective Cohort Study on Comparison the Efficacy and Safety of SOX and XELOX as Adjuvant Chemotherapy in Gastric Cancer after D2 Gastrectomy

作　　者：周虹[1] 蔡文杰[2] 林燕芳[1] 林志强[1] 何晓梦 Zhou Hong;Cai Wenjie;Lin Yanfang;Lin Zhiqiang;He Xiaomeng(Department of Pharmacy,Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou 362000,Fujian,China;Department of Radiation Oncology,Quanzhou First Hospital Affiliated to Fujian Medical University;Department of Pharmacy,The First Affiliated Hospital of Dalian Medical University)

机构地区：[1]福建医科大学附属泉州第一医院药剂科,福建泉州362000 [2]福建医科大学附属泉州第一医院放疗科 [3]大连医科大学附属第一医院

出　　处：《药物流行病学杂志》2018年第11期725-728,共4页Chinese Journal of Pharmacoepidemiology

基　　金：泉州市卫计委卫生科研课题(编号:泉卫计办[2016]33号);泉州市第一医院青年科研课题(编号:2014-QN-17)

摘　　要：目的:对比奥沙利铂联合替吉奥(SOX)与奥沙利铂联合卡培他滨(XELOX)两种化疗方案在胃癌D2根治术后辅助化疗中的有效性和安全性。方法:采用回顾性队列研究方法,对2011～2013年在我院采用SOX或XELOX方案行辅助化疗的胃癌D2根治术患者,随访观察总生存率(OS)、无病生存期(DFS)和药品不良反应。结果:共43例胃癌D2根治术患者进行辅助化疗,SOX组23例,XELOX组20例,中位随访时间为59个月。SOX组和XELOX组5年总生存率分别为39. 1%和51. 5%,中位DFS分别为46. 5个月和41. 67个月,两组比较差异均无统计学意义(P> 0. 05)。3～4度不良反应总发生率SOX组和XELOX组分别为26. 09%和20. 0%,差异无统计学意义(P> 0. 05),主要表现为中性粒细胞减少和恶心呕吐。结论:胃癌D2根治术后辅助化疗中的SOX疗效和安全性未优于XELOX。Objective：To compare the efficacy and safety of oxaliplatin plus S-1（ SOX） versus oxaliplatin puls capecitabine（ XELOX） as adjuvant chemotherapy after D2 dissection for gastric cancer. Methods： Between 2011 and2013,patients in our hospital who underwent D2 dissection for gastric cancer were retrospectively reviewed and followed-up to analyze the overall survival,disease free survival and safety of SOX and XELOX. Results：43 patients were enrolled into this study according to the established inclusion and exclusion criteria. 23 received the SOX regimen and 20 received XELOX therapy. At the median follow-up of 59 months,the 5-year OS rates（39. 1% vs. 51. 5%,P 〉 0. 05） and diseasefree survival（46. 5 months vs. 41. 67 months,P 〉 0. 05） no differed significantly between two groups. The rates of grade3-4 adverse events were 26. 09% and 20. 0%,respectively,for SOX and XELOX group（ P 〉 0. 05）. Neutropenia,nausea/vomiting and anorexia were the major treatment-related adverse events. Conclusion：Adjuvant SOX therapy appears not to be associated with superior efficacy than XELOX after D2 dissection for gastric cancer.

关 键 词：胃癌 SOX XELOX 辅助化疗 回顾性队列研究 

分 类 号：R735.2[医药卫生—肿瘤]